Browsing by Author "Başyiğit İ."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    COVID-19: booster(s) vs. hospitalization and Intensive Care Unit admission
    (Verduci Editore s.r.l, 2023) Toprak O.B.; Akpolat T.; Uzun O.; Pinar Deniz P.; Kokturk N.; Varol A.; Guzel E.; Ercelik M.; Gultekin O.; Guner R.; Turan S.; Gökbulut Bektaş Ş.; Coskun N.; Bakan N.; Nuri Yakar M.; Eren Kutsoylu O.; Ergan B.; Argun Bariş S.; Başyiğit İ.; Boyaci H.; Çetinkaya F.; Çolak H.; Aykac N.; Baran Ketencioğlu B.; Türe Yüce Z.; Akkaya Isik S.; Serap Yilmaz E.; Karaoğlanoğlu S.; Berik Safci S.; Ozkan G.; Kose N.; Kizilirmak D.; Havlucu Y.; Nural S.; Kerget F.; Sunal Ö.; Yuksel A.; Bestepe Dursun Z.; Deveci F.; Kuluozturk M.; Ataoglu O.; Dursun M.; Keskin S.; Emin Sezgin M.; Aktepe Sezgin E.N.; Eser F.; Akyildiz L.; Selim Almaz M.; Kayaaslan B.; Hasanoğlu İ.; Bayrak M.; Gümüş A.; Sağcan G.; Cuhadaroglu C.; Kucuk H.; Onyilmaz T.; Mete B.; Kilinc O.; Oya Itil B.
    OBJECTIVE: As the pandemic continues, different vaccine protocols have been implemented to maintain the protection of vaccines and to provide protection against new variants. The aim of this study was to assess hospitalized patients' vaccination status and document the efficacy of boosters. PATIENTS AND METHODS: The patients that were hospitalized due to COVID-19 were enrolled from 28 hospitals in Turkey for five months from September 2021. 5,331 confirmed COVID-19 patients from collaborating centers were randomly enrolled to understand/estimate the distribution of vaccination status in hospitalized patients and to compare the efficacy of vaccination/booster protocols. RESULTS: 2,779 men and 2,552 women of which 2,408 (45.2%) were admitted to Intensive Care Units participated in this study. It was found that the highest risk reduction for all age groups was found in groups that received 4 doses. Four doses of vaccination for every 3.7 people under 50 years of age, for every 5.7 people in the 50-64 age group, and for every 4.3 people over 65 years of age will prevent 1 patient from being admitted to intensive care. Regardless of the type of vaccine, it was found that the risk of ICU hospitalization decreased in those who were vaccinated compared to those who were not vaccinated. Regardless of the type of vaccine, the ICU risk was found to decrease 1.25-fold in those who received 1 or 2 doses of vaccine, 1.18-fold in those who received 3 doses, and 3.26-fold in those who received 4 doses. CONCLUSIONS: The results suggested that the addition of a fourth dose is more effective in preventing intensive unit care even in disadvantaged. © 2023 Verduci Editore s.r.l. All rights reserved.
  • No Thumbnail Available
    Item
    Asthma-chronic obstructive pulmonary disease overlap: Results from a national-multicenter study; [Astım KOAH overlap: Ulusal çok merkezli bir çalışma sonuçları]
    (Ankara University, 2024) Çelik G.E.; Aydin Ö.; Şen E.; Demir T.; Gemicioğlu B.; Kiyan E.; Mungan D.; Kivilcim Oğuzülgen İ.; Polatli M.; Göksel Ö.; Sayiner A.; Yildirim N.; Yildiz F.; Yorgancioğlu A.; Elhan A.H.; Yildiz Ö.; Başyiğit İ.; Börekçi Ş.; Havlucu Y.; Okumuş G.; Türk M.; Saryal S.
    Introduction: Patients with asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) have a greater disease burden than those with COPD or asthma alone. In this study, it was aimed to determine the prevalence, risk factors, and clinical features of ACO because there are limited national data in Türkiye. Materials and Methods: The study was conducted in a cross-sectional design in nine tertiary-care hospitals. The patients followed with a diagnosis of asthma or COPD for at least one year were enrolled in the study. The frequency of ACO and the characteristics of the patients were evaluated in the asthma and COPD groups. Results: The study included 408 subjects (F/M= 205/203, mean age= 56.24 ± 11.85 years). The overall prevalence of ACO in both groups was 20.8% (n= 85). The frequency was higher in the COPD group than in the asthma group (n= 55; 33.3% vs. n= 22; 9.8%), respectively (p= 0.001). Patients with ACO had similarities to patients with COPD in terms of advanced age, sex, smoking, exposure to biomass during childhood, being born in rural areas, and radio-logic features. Characteristics such as a history of childhood asthma and allergic rhinitis, presence of chronic sinusitis, NSAID hypersensitivity, atopy, and high eosinophil counts were similar to those of patients with asthma (p< 0.001). The annual decline in FEV1 was more prominent in the ACO group (mean=-250 mL) than in the asthma (mean change=-60 mL) and COPD (mean change=-230 mL) groups (p= 0.003). Conclusion: This study showed that ACO was common among patients with asthma and COPD in tertiary care clinics in our country. ACO should be considered in patients with asthma and COPD who exhibit the abovementioned symptoms. © 2024 by Tuberculosis and Thorax.